Update: Drug shortages business opportunity gains steam

I liked getting mail when I was a kid, and it's the same today. Thanks to all who wrote in support of my editorial last week on the possibility of a business opportunity: a drug manufacturing niche addressing ongoing shortages.

CEOs, presidents, the principal at a consulting and sourcing company and a VP for business strategy from companies in the U.S., U.K, Italy and China are among those who wrote. They offered pharma- or business-related services and insights--including help with the business plan and with making connections--or they expressed that the drug-shortage niche had occurred as a business opportunity to them, too.

Fortified with this support, I'm now plying my editorial sources for manufacturing, business, regulatory and IP to get their read.

More reports as developments arise. In the meantime, keep the e-mails coming. - George Miller

Suggested Articles

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

The FDA recently asked five drug manufacturers to recall the commonly used diabetes med metformin. With COVID-19 raging, is metformin just the start?

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.